{
  "subset": "contraindication",
  "disease": "Primary membranoproliferative glomerulonephritis",
  "relation": "contraindication",
  "gold_drugs": [
    "aliskiren",
    "alxn1720",
    "apl-2",
    "avacopan",
    "avacopan matching placebo",
    "bcx9930",
    "belimumab injection",
    "cdx-1135",
    "cyclosporin",
    "danicopan",
    "daratumumab",
    "eculizumab",
    "enalapril",
    "iptacopan",
    "lnp023",
    "pegcetacoplan",
    "rituximab",
    "sgb-9768"
  ],
  "seeds_initial": [
    "Prednisone",
    "Rituximab",
    "Cyclophosphamide",
    "Tacrolimus",
    "NSAIDs",
    "ACE inhibitors",
    "ARBs",
    "Diuretics",
    "Immunosuppressants",
    "Corticosteroids",
    "Cyclosporine",
    "Methotrexate"
  ],
  "seed_history": [
    [
      "Prednisone",
      "Rituximab",
      "Cyclophosphamide",
      "Tacrolimus",
      "NSAIDs",
      "ACE inhibitors",
      "ARBs",
      "Diuretics",
      "Immunosuppressants",
      "Corticosteroids",
      "Cyclosporine",
      "Methotrexate"
    ]
  ],
  "final_report": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_prednisone",
          "name": "Prednisone"
        },
        "score": 0.15,
        "graph_snapshot_ref": "GE_H1_round3",
        "key_assumptions": [
          "Prednisone在炎症控制中潜在有效",
          "现有不良反应风险显著并需监测"
        ],
        "caveats": [
          "不良结果的风险高，可能完全抵消潜在益处"
        ],
        "confidence": "low"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_rituximab",
          "name": "Rituximab"
        },
        "score": 0.15,
        "graph_snapshot_ref": "GE_H2_round3",
        "key_assumptions": [
          "靶向作用可能改善病理",
          "不良反应需严格监控"
        ],
        "caveats": [
          "安全性数据不足"
        ],
        "confidence": "low"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_cyclophosphamide",
          "name": "Cyclophosphamide"
        },
        "score": 0.15,
        "graph_snapshot_ref": "GE_H3_round3",
        "key_assumptions": [
          "作为化疗药物的有效性",
          "安全性问题需关注"
        ],
        "caveats": [
          "治疗效果未被充分验证"
        ],
        "confidence": "low"
      },
      {
        "hypothesis_id": "H4",
        "candidate": {
          "id": "drug_tacrolimus",
          "name": "Tacrolimus"
        },
        "score": 0.15,
        "graph_snapshot_ref": "GE_H4_round3",
        "key_assumptions": [
          "免疫抑制的理论有效性",
          "追踪不良反应非常重要"
        ],
        "caveats": [
          "缺乏临床证据支持"
        ],
        "confidence": "low"
      },
      {
        "hypothesis_id": "H5",
        "candidate": {
          "id": "drug_nsaids",
          "name": "NSAIDs"
        },
        "score": 0.15,
        "graph_snapshot_ref": "GE_H5_round3",
        "key_assumptions": [
          "炎症减轻可能有益",
          "不良反应需进一步评估"
        ],
        "caveats": [
          "安全性数据支持不足"
        ],
        "confidence": "low"
      },
      {
        "hypothesis_id": "H6",
        "candidate": {
          "id": "drug_ace_inhibitors",
          "name": "ACE inhibitors"
        },
        "score": 0.15,
        "graph_snapshot_ref": "GE_H6_round3",
        "key_assumptions": [
          "免疫机制影响的潜力",
          "不良结果风险需重视"
        ],
        "caveats": [
          "缺乏广泛的临床支持"
        ],
        "confidence": "low"
      },
      {
        "hypothesis_id": "H7",
        "candidate": {
          "id": "drug_arbs",
          "name": "ARBs"
        },
        "score": 0.15,
        "graph_snapshot_ref": "GE_H7_round3",
        "key_assumptions": [
          "抗炎作用可能带来的好处",
          "安全性存在的隐患需考量"
        ],
        "caveats": [
          "现有证据支持不足"
        ],
        "confidence": "low"
      },
      {
        "hypothesis_id": "H8",
        "candidate": {
          "id": "drug_diuretics",
          "name": "Diuretics"
        },
        "score": 0.15,
        "graph_snapshot_ref": "GE_H8_round3",
        "key_assumptions": [
          "对液体平衡影响的作用",
          "密切监控可能的不良影响"
        ],
        "caveats": [
          "安全性证据不足"
        ],
        "confidence": "low"
      },
      {
        "hypothesis_id": "H9",
        "candidate": {
          "id": "drug_immunosuppressants",
          "name": "Immunosuppressants"
        },
        "score": 0.15,
        "graph_snapshot_ref": "GE_H9_round3",
        "key_assumptions": [
          "炎症控制的有效性质",
          "安全性需严格评估"
        ],
        "caveats": [
          "临床证据支持不足"
        ],
        "confidence": "low"
      },
      {
        "hypothesis_id": "H10",
        "candidate": {
          "id": "drug_corticosteroids",
          "name": "Corticosteroids"
        },
        "score": 0.15,
        "graph_snapshot_ref": "GE_H10_round3",
        "key_assumptions": [
          "强效抗炎性能通过控制症状",
          "需分心监测潜在的不良反应"
        ],
        "caveats": [
          "风险因素必须考虑"
        ],
        "confidence": "low"
      },
      {
        "hypothesis_id": "H11",
        "candidate": {
          "id": "drug_cyclosporine",
          "name": "Cyclosporine"
        },
        "score": 0.15,
        "graph_snapshot_ref": "GE_H11_round3",
        "key_assumptions": [
          "免疫调节特性可能有益",
          "不良反应需认真评估"
        ],
        "caveats": [
          "缺乏足够临床支持"
        ],
        "confidence": "low"
      },
      {
        "hypothesis_id": "H12",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        },
        "score": 0.15,
        "graph_snapshot_ref": "GE_H12_round3",
        "key_assumptions": [
          "免疫调节潜力的理论支持",
          "不良反应将影响患者"
        ],
        "caveats": [
          "现有数据不足"
        ],
        "confidence": "low"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "多种药物与不良结果相关，需严格风险评估",
          "reason": "现有候选的安全风险较高，且支持数据薄弱"
        }
      ],
      "remaining_gaps": [
        "对现有方案的有效性和安全性缺乏完整的证据"
      ]
    },
    "seed_retrospective": {
      "batches": [
        {
          "round": 1,
          "seeds": [
            "A",
            "B"
          ],
          "impact_summary": "未有效提升安全性评估"
        },
        {
          "round": 2,
          "seeds": [
            "C",
            "D"
          ],
          "impact_summary": "安全性问题依然突出"
        }
      ],
      "lessons": [
        "需重点关注伴随疗效的安全性问题",
        "需平衡潜在益处与风险"
      ]
    },
    "prompt_patches": [],
    "heuristics": []
  },
  "experience_used": true,
  "explorer_prompt": "List drugs that are contraindicated or could worsen the rare disease 'Primary membranoproliferative glomerulonephritis'. Return only names.\n\n# Prior guidance for Explorer:\n- 在候选中加入不同机制的药物，以充实证据链和降低风险。\n\n# Heuristics:\n- When 有相关的免疫疾病: then 关注药物对免疫系统的影响程度及长期效果。\n- When 存在旁靶风险: then 开展临床观察以监测不良反应和效果。"
}